Summer 2026

Data Engineering & Analytics Intern

Posted on 3/24/2026

Doximity

Doximity

501-1,000 employees

Professional networking, residency tools, telehealth

No salary listed

San Francisco, CA, USA

Hybrid

Three days on-site per week in SF (Mon/Tue/Thu).

Bachelor's

Category
Data & Analytics (2)
,
Required Skills
LLM
Python
Data Structures & Algorithms
SQL
Machine Learning
Data Engineering
Pandas
NumPy
Data Analysis

Get referred to Doximity

See people who can refer or advise you

Requirements
  • Currently pursuing a degree in Data Science, Computer Science, Data Engineering, or a related field.
  • Completed coursework in ML/AI concepts and are eager to apply what you’ve learned to help build, evaluate, and improve AI-driven products.
  • Working knowledge of SQL, including writing queries that join multiple tables and perform aggregations.
  • Experience using Python for end-to-end data analysis, applying statistical thinking, performing aggregations with tools like Pandas and NumPy, and translating results into clear visualizations and narratives.
  • Basic understanding of programming fundamentals, including functions, data structures, and introductory object-oriented concepts in Python.
  • Interest in learning how to build maintainable and reliable data workflows, with guidance from senior team members.
  • Curiosity about how data products are built end-to-end, from problem definition to delivering analysis or code.
  • Demonstrated ability to learn quickly, ask thoughtful questions, and incorporate feedback.
Responsibilities
  • Contribute to the measurement, analysis, and evolution of AI-powered products at Doximity.
  • Collaborate with data analysts, data engineers, and developers to help design, implement, and evaluate LLM-based approaches that inform future product iterations.
  • Work with real production datasets to support data analysis, pipelines, and dashboards used across the business.
  • Learn and apply best practices for writing clean, maintainable, and well-tested data code.
  • Gain hands-on exposure to modern data tooling, distributed data processing, and ML/AI workflows.
  • Participate in projects end-to-end — from problem definition through delivery — with mentorship and support from the team.

Doximity is a digital platform for United States healthcare professionals, offering a professional social network, a residency navigator, and telehealth services. Users join to connect with peers, share medical insights, track residency applications, and conduct remote patient visits. Revenue comes from targeted advertising to medical professionals, premium subscriptions, and telehealth usage fees. Its goal is to improve communication and collaboration among clinicians, support career development and residency placement, and expand access to care through convenient telehealth.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2010

Get referred to Doximity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 revenue hit $156.6 million, beating estimates and lifting full-year guidance.
  • Management said AI Search earns over 10 times its operating cost.
  • Workflow prescribers grew over 30% and AI Search queries rose over 25% quarter-over-quarter.

What critics are saying

  • Fading growth and lower margins follow 2026 guidance of 4% revenue growth.
  • The $31 million securities settlement and SEC insider-trading case damage trust.
  • AI economics depend on pharma budgets; if adoption stalls, the valuation rerates fast.

What makes Doximity unique

  • Doximity reaches over 80% of U.S. physicians, giving unmatched clinical distribution.
  • Its AI Search and Scribe products embed workflow tools inside physician daily habits.
  • Pharma clients buy targeted access to verified doctors, not generic healthcare ad inventory.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Family Planning Benefits

Paid Vacation

Paid Holidays

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Aug 12th, 2026
Dutch Bros eyed as cash-producing coffee chain expanding rapidly with 27.7% growth forecast

Dutch Bros, the US coffee chain, is attracting attention for its strong same-store sales performance and expansion strategy. The company has achieved average same-store sales growth of 6% over the past two years and expects revenue growth of 27.7% for the next year. Meanwhile, two cash-generating companies face challenges. Doximity, the physician networking platform, has seen costs rise faster than revenue, with operating margins declining by 10.5 percentage points. Its estimated sales growth of 4.6% for the next 12 months suggests slowing demand. Silgan Holdings, the packaging supplier, has experienced annual revenue growth of just 4.7% over five years and earnings per share growth of only 2.4% annually.

Yahoo Finance
Aug 11th, 2026
Doximity's Q2 revenue rises 7.3% to $156.6M as AI adoption surges among clinicians

Doximity reported Q2 revenue of $156.6 million, up 7.3% year on year and beating analyst estimates of $151.3 million. The medical professional network's adjusted earnings per share of $0.29 missed expectations by 4.2%. The company attributed growth to increased adoption of AI-powered clinical tools. CEO Jeffrey Tangney noted quarterly active workflow prescribers grew more than 30% year on year, with nearly half using AI tools. Operating margin declined to 21.5% from 37.4% in the prior year period. The company raised full-year revenue guidance to $676 million from $670 million but set EBITDA guidance below analyst estimates at $319 million. CFO Matthew Sonefeldt said higher AI usage prompted increased investment to capture long-term opportunities, explaining near-term margin pressure.

Yahoo Finance
Aug 10th, 2026
Wells Fargo downgrades Doximity to underweight with $18 target after 33% post-earnings pop

Wells Fargo downgraded Doximity to Underweight from Equal Weight with an $18 price target, days after the medical professionals' digital platform surged 32.58% on earnings. Analyst Stan Berenshteyn noted that whilst Doximity's outlook remains unchanged, the stock now trades near faster-growing peers at approximately 32 times earnings despite roughly 11% revenue growth over the past year. The analyst argued remaining upside depends on an AI narrative that is difficult to quantify in estimates. Survey work suggests wallet-share gains with top accounts are largely complete. The $18 target sits at the bottom of analyst estimates ranging to $47. Wells Fargo cited unfavourable risk-reward until Doximity's AI strategy produces clearer growth acceleration.

Yahoo Finance
Aug 8th, 2026
Doximity raises revenue outlook to $671M-681M as clinical AI tools drive uptake

Doximity reported fiscal first-quarter 2027 results with revenue rising to $156.62 million from $145.91 million year-over-year, though net income and earnings per share declined. The company raised its guidance to $170–171 million for second-quarter revenue and $671–681 million for the full year, citing rapid uptake of its clinical AI tools. The healthcare network is monetising physician engagement through software and marketing revenue, now enhanced by clinical AI capabilities. Key near-term catalysts include how quickly AI tools convert to contracted revenue and whether health systems expand adoption. Despite the stock's 31% rise, fair value estimates from the Simply Wall St Community range from roughly $18 to under $36.72, reflecting varied views on Doximity's AI opportunity. Main risks include execution challenges, management changes, and potential slowdowns in pharmaceutical spending.

NDTV Profit
Aug 7th, 2026
This digital healthcare stock spikes 100% after cracking The AI code.

This digital healthcare stock spikes 100% after cracking The AI code. Read Time: 4 mins AI Generated Image Shares of Doximity Inc. surged in premarket trading on Friday after the digital medical platform's management revealed strong economics for its new AI-powered search product, with the stock gaining more than 130% at one point before paring some of those gains after the US market opened. The rally followed comments from CEO Jeffrey Tangney, who said Doximity is generating more than 10 times the revenue per AI search than the cost of running it. The comments have fuelled expectations that the company's AI investments could open a significantly larger market while supporting stronger long-term margins. "It's early days on our AI search product, but I can tell you we're earning more than 10 times per search in revenue than it costs," Tangney said during Doximity's first-quarter fiscal 2027 earnings call on Thursday, as per CNBC. He added that AI costs could decline further as models become more efficient, potentially improving the economics of the product over time. Doximity Raises Revenue Outlook The AI opportunity comes on top of an already strong quarterly performance. Doximity reported first-quarter revenue of $156.6 million and adjusted EBITDA of $74.8 million, with both figures exceeding consensus estimates. The company also raised its full-year fiscal 2027 revenue guidance by $6 million, or about 5%, to a range of $671 million-$681 million. However, analysts believe the upgraded guidance may not fully reflect the potential contribution from Doximity's expanding AI business. Piper Sandler analyst Jessica Tassan said the fiscal 2027 guidance increase was largely driven by the first-quarter beat and did not include a significant contribution from the growing AI commercial pipeline discussed by management, CNBC reports. She described the company's approach to forecasting AI search revenue as conservative. That leaves room for the AI product to become an additional growth driver if adoption accelerates. AI Search Could Expand Doximity's Market Tangney also indicated that the impact of AI search could extend beyond improving the economics of Doximity's existing business. The CEO said the technology had unexpectedly expanded the company's total addressable market (TAM) across the healthcare and pharmaceutical sectors. That potential has attracted attention from analysts. Michael Cherney of Leerink Partners said the AI search product is strengthening confidence that Doximity's increased investment in artificial intelligence could ultimately support attractive long-term margins. The economics are particularly notable because AI products typically require significant computing resources. If Doximity can generate substantially more revenue from each search than the cost of operating it, rising usage could potentially translate into meaningful incremental profitability. Tangney also expects the cost side of the equation to improve as AI models become more efficient. Short Sellers Add Fuel To Doximity Rally The sharp move in Doximity shares may also have been amplified by positioning in the stock. Around 17% of Doximity's freely tradable shares were sold short heading into the earnings announcement, according to FactSet. The stronger-than-expected financial results and bullish comments around AI could have forced some short sellers to buy back shares to close their positions. Such buying can accelerate a stock's rise, creating what is commonly known as a short squeeze. Doximity had entered Friday's session under considerable pressure. The stock was down around 50% for the year before the latest earnings report, with the company valued at about $3.7 billion before the surge. The combination of heavy short interest, strong quarterly numbers and the unexpectedly high profitability of its AI search product therefore created a powerful catalyst for the stock. Doximity Stock Performance Doximity shares rose more than 130% in premarket trading at their peak on Friday before giving up part of the gain after the regular session began. The stock was last reported up around 55% in the supplied market update. As of 7 August 2026, 12:06 p.m. GMT-4, Doximity was trading at $27.79, up 34.51%, or $7.13, from the previous close of $20.66. The stock opened at $38.86 and touched an intraday high of $40, before falling to an intraday low of $27.75. Its 52-week range stood at $17.15-$76.51. Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories - On NDTV Profit.

INACTIVE